PF-08046052
- Generic Name
- PF-08046052
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell LungPancreatic Ductal AdenocarcinomaColorectal NeoplasmsSquamous Cell Carcinoma of the Head and Neck
- Interventions
- Drug: SGN-EGFRd2
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 290
- Registration Number
- NCT05983133
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology & Oncology, Santa Monica, California, United States
🇺🇸Moffitt Cancer Center McKinley Hospital, Tampa, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath